Clinical Trials

Breaking News: FDA Approves Vorasidenib (Voranigo®)

A great day for Low Grade Astrocytoma and Oligodendroglioma Patients with IDH1/IDH2 Mutations

Aug 6 •

Scott L. Rakestraw, PhD

Michael Lim, MD – Brain Cancer Science Talk (Episode 7)

Stanford’s Chair of Neurosurgery discusses the promise and challenges associated with immunotherapy for brain tumors

Jul 15 •

Scott L. Rakestraw, PhD

30:07

The Reality of Clinical Trials – Part 2

Bess Stillman, MD details how the Regulatory process needs to be modernized to better serve both cancer patients and Sponsors. We extend the concepts to…

Jul 2 •

Scott L. Rakestraw, PhD

The Reality of Clinical Trials - Part 1

Often a frustrating slog through inaccurate information and hidden conflicts of interest

Apr 10 •

Scott L. Rakestraw, PhD

Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients

Big Study. Muddy Biology. Ugh!

Mar 29 •

Scott L. Rakestraw, PhD

Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC

Promising, but we will wait for the full data presentation

Mar 27 •

Scott L. Rakestraw, PhD

Breakthrough Results from the INDIGO Trial of Vorasidenib in Low Grade Glioma (LGG)

Great news for IDH-mutant LGG patients…and an object lesson in investable theses for brain cancer

Jun 7, 2023 •

Scott L. Rakestraw, PhD

Day One Biopharmaceuticals Announces Top Line Data for the FIREFLY-1 Pivotal Phase 2 Trial in Pediatric Low Grade Glioma

Meaningful clinical responses to tovorafenib suggest an important new tool in the Brain Cancer Toolbox

Jan 12, 2023 •

Scott L. Rakestraw, PhD

Big News: Moderna and Merck Report Phase 2b Data for an mRNA Cancer Vaccine + Pembrolizumab

Further Evidence that the Central Hypothesis is gaining traction in cancer immunotherapy

Dec 14, 2022 •

Scott L. Rakestraw, PhD

SNO Storm: Phase 3 Results for DCVax-L

Highlights from the Society for Neuro-Oncology (SNO) 2022 Annual Meeting

Nov 18, 2022 •

Scott L. Rakestraw, PhD

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts